Imperial College London
Alternate

Professor Irene Roberts

Faculty of Medicine, Department of Immunology and Inflammation

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 3313 2163irene.roberts

 
 
//

Assistant

 

Miss Karen Linfield +44 (0)20 3313 3238

 
//

Location

 

4S10BHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Engert:2016:10.3324/haematol.2015.136739,
author = {Engert, A and Balduini, C and Brand, A and Coiffier, B and Cordonnier, C and Döhner, H and de, Wit TD and Eichinger, S and Fibbe, W and Green, T and de, Haas F and Iolascon, A and Jaffredo, T and Rodeghiero, F and Salles, G and Schuringa, JJ and EHA, Roadmap for European Hematology Research},
doi = {10.3324/haematol.2015.136739},
journal = {Haematologica},
pages = {115--208},
title = {The European Hematology Association Roadmap for European Hematology Research: a consensus document.},
url = {http://dx.doi.org/10.3324/haematol.2015.136739},
volume = {101},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap.The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders.The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
AU  - Engert,A
AU  - Balduini,C
AU  - Brand,A
AU  - Coiffier,B
AU  - Cordonnier,C
AU  - Döhner,H
AU  - de,Wit TD
AU  - Eichinger,S
AU  - Fibbe,W
AU  - Green,T
AU  - de,Haas F
AU  - Iolascon,A
AU  - Jaffredo,T
AU  - Rodeghiero,F
AU  - Salles,G
AU  - Schuringa,JJ
AU  - EHA,Roadmap for European Hematology Research
DO  - 10.3324/haematol.2015.136739
EP  - 208
PY  - 2016///
SN  - 0390-6078
SP  - 115
TI  - The European Hematology Association Roadmap for European Hematology Research: a consensus document.
T2  - Haematologica
UR  - http://dx.doi.org/10.3324/haematol.2015.136739
UR  - http://www.ncbi.nlm.nih.gov/pubmed/26819058
UR  - http://hdl.handle.net/10044/1/43287
VL  - 101
ER  -
Download